Analysis Result #1362

{
  "analysis": {
    "input_data": {
      "article": "Title: Granules India arm receives USFDA inspection report for Virginia facility, single observation resolved\n\nPublished: 2025-11-05\n\nContent: \u201cThere was one observation during the inspection, and it has been resolved,\u201d the Hyderabad-based company informed the bourses.",
      "full_prompt_sent_to_llm": "=== NEWS ARTICLE ===\nTitle: Granules India arm receives USFDA inspection report for Virginia facility, single observation resolved\n\nPublished: 2025-11-05\n\nContent: \u201cThere was one observation during the inspection, and it has been resolved,\u201d the Hyderabad-based company informed the bourses.\n\n=== TOP MATCHING STOCK FROM RAG ===\n\nSymbol: GRANULES.NS\nCompany: Granules India Limited\nSector: Healthcare\nIndustry: Drug Manufacturers - Specialty \u0026 Generic\nSimilarity Score: 0.4804 (48.04%)\n\nMarket Data:\n\u2022 Current Price: 557.15\n\u2022 Previous Close: 570.05\n\u2022 Day Low: 554.45\n\u2022 Day High: 573.75\n\u2022 52-Week Low: 422.0\n\u2022 52-Week High: 628.0\n\u2022 Volume: 1238648\n\u2022 Avg Volume: 1648069\n\nAdvanced Technical Indicators (21 total):\nClose_3d:565.80,570.05,557.15 | RSI:56.02 | MACD:12.970/14.272/-1.301 | BB:591.27/551.80/512.33 | MA:551.80/519.88 | ATR:14.70 | OBV:45,558,102 | WillR:-66.48 | CMF:0.0088 | Ichi:570.83/548.88/559.85/510.60 | PSAR:574.83 | Aroon:80.00/32.00 | VWAP:498.16 | Force:2059127.66 | Mass:24.87 | Coppock:2.90 | UltOsc:37.27\n\nQuantitative Risk \u0026 Performance Metrics (35 total):\nAvgVol:1,603,157 | Price:557.15 | VaR:-0.0352/-0.0674 | CVaR:-0.0568/-0.0872 | Std:0.0229 | AnnVol:0.3634 | DownDev:0.0246 | Skew:-0.6539 | Kurt:2.3106 | Sharpe:0.1084 | MaxDD:-0.3003 | VolRat:2.4226 | P/MA20:1.0097 | P/MA50:1.0717 | VolReg:0.8641 | Mom:0.0586/0.1744 | MeanRet:0.0002 | W/L:1.08 | Amihud:0.000000 | Roll:0.000000 | VolSurp:0.0780 | Omega:1.0261 | Sortino:0.1390 | TailR:1.0150 | ESRat:1.6150 | Hurst:0.1948 | HalfL:20.30 | Mom120:0.2331 | ApEn:0.7277\n\n=== ANALYZE THE ARTICLE (use RAG context if relevant) ===",
      "rag_context": {
        "company": "Granules India Limited",
        "country": "India",
        "description_preview": "[STOCK SYMBOL]: GRANULES.NS\n[COMPANY NAME]: Granules India Limited\n[SECTOR]: Healthcare\n[INDUSTRY]: Drug Manufacturers - Specialty \u0026 Generic\n[COUNTRY]: India\n------------------------------------------...",
        "full_description": "[STOCK SYMBOL]: GRANULES.NS\n[COMPANY NAME]: Granules India Limited\n[SECTOR]: Healthcare\n[INDUSTRY]: Drug Manufacturers - Specialty \u0026 Generic\n[COUNTRY]: India\n--------------------------------------------------------------------------------\ncountry - India\nindustry - Drug Manufacturers - Specialty \u0026 Generic\nsector - Healthcare\nlongBusinessSummary - Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.\nfullTimeEmployees - 4066\npreviousClose - 570.05\nopen - 572.9\ndayLow - 554.45\ndayHigh - 573.75\nregularMarketDayLow - 554.45\nregularMarketDayHigh - 573.75\ndividendRate - 1.5\ndividendYield - 0.26\nexDividendDate - 1753920000\npayoutRatio - 0.0759\nfiveYearAvgDividendYield - 0.36\nbeta - -0.082\ntrailingPE - 28.167341\nvolume - 1238648\nregularMarketVolume - 1238648\naverageVolume - 1648069\naverageVolume10days - 1206511\naverageDailyVolume10Day - 1206511\nmarketCap - 135202881536\nfiftyTwoWeekLow - 422.0\nfiftyTwoWeekHigh - 628.0\npriceToSalesTrailing12Months - 2.996618\nfiftyDayAverage - 520.253\ntwoHundredDayAverage - 504.01025\ntrailingAnnualDividendRate - 0.0\ntrailingAnnualDividendYield - 0.0\ncurrency - INR\nenterpriseValue - 148119928832\nforwardPE - 19.332062\nprofitMargins - 0.10628\nfloatShares - 141570342\nsharesOutstanding - 242668716\nheldPercentInsiders - 0.40147\nheldPercentInstitutions - 0.24716999\nbookValue - 153.192\npriceToBook - 3.6369393\nearningsQuarterlyGrowth - -0.163\nnetIncomeToCommon - 4795039744\ntrailingEps - 19.78\nenterpriseToRevenue - 3.283\nenterpriseToEbitda - 16.371\nlastDividendValue - 1.5\nquoteType - EQUITY\ncurrentPrice - 557.15\ntargetHighPrice - 700.0\ntargetLowPrice - 480.0\ntargetMeanPrice - 578.1429\ntargetMedianPrice - 534.0\nrecommendationMean - 1.42857\nrecommendationKey - strong_buy\nnumberOfAnalystOpinions - 7\ntotalCash - 4689690112\ntotalCashPerShare - 19.335\nebitda - 9047895040\ntotalDebt - 14547569664\ntotalRevenue - 45118488576\ndebtToEquity - 39.153\nrevenuePerShare - 186.014\ngrossProfits - 27150469120\nearningsGrowth - -0.164\nrevenueGrowth - 0.026\ngrossMargins - 0.60175997\nebitdaMargins - 0.20054\noperatingMargins - 0.14699\nexchange - NSI\nregularMarketPrice - 557.15\nshortName - GRANULES INDIA LIMITED\nlongName - Granules India Limited\nepsTrailingTwelveMonths - 19.78\nepsCurrentYear - 22.95\ntrailingPegRatio - None\n--------------------------------------------------------------------------------\n[BUSINESS SUMMARY]\nGranules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.\n--------------------------------------------------------------------------------\n[IMPORTANT METRICS]\nCompany: Granules India Limited\nSector: Healthcare\nIndustry: Drug Manufacturers - Specialty \u0026 Generic\nCountry: India\nMarket Cap: 135.20B\nCurrent Price: 557.15\nP/E Ratio: 28.167341\nP/B Ratio: 3.6369393\nDividend Yield: 0.2600%\nProfit Margin: 0.1063\nBeta: -0.0820\nVolume: 1,238,648\nAvg Volume: 1,648,069\nDay Range: 554.45 - 573.75\n52Wk Range: 422.0 - 628.0\nTotal Revenue: 45118488576\nTotal Cash: 4.69B\nTotal Debt: 14.55B\nDebt to Equity: 39.153\nTarget Price: 480.0 - 700.0\nAnalyst Opinions: 7\nRecommendation: strong_buy\n--------------------------------------------------------------------------------\n[TECHNICAL] Close_3d:565.80,570.05,557.15 | RSI:56.02 | MACD:12.970/14.272/-1.301 | BB:591.27/551.80/512.33 | MA:551.80/519.88 | ATR:14.70 | OBV:45,558,102 | WillR:-66.48 | CMF:0.0088 | Ichi:570.83/548.88/559.85/510.60 | PSAR:574.83 | Aroon:80.00/32.00 | VWAP:498.16 | Force:2059127.66 | Mass:24.87 | Coppock:2.90 | UltOsc:37.27\n--------------------------------------------------------------------------------\n[QUANT] AvgVol:1,603,157 | Price:557.15 | VaR:-0.0352/-0.0674 | CVaR:-0.0568/-0.0872 | Std:0.0229 | AnnVol:0.3634 | DownDev:0.0246 | Skew:-0.6539 | Kurt:2.3106 | Sharpe:0.1084 | MaxDD:-0.3003 | VolRat:2.4226 | P/MA20:1.0097 | P/MA50:1.0717 | VolReg:0.8641 | Mom:0.0586/0.1744 | MeanRet:0.0002 | W/L:1.08 | Amihud:0.000000 | Roll:0.000000 | VolSurp:0.0780 | Omega:1.0261 | Sortino:0.1390 | TailR:1.0150 | ESRat:1.6150 | Hurst:0.1948 | HalfL:20.30 | Mom120:0.2331 | ApEn:0.7277",
        "industry": "Drug Manufacturers - Specialty \u0026 Generic",
        "sector": "Healthcare",
        "similarity_score": 0.480369568,
        "symbol": "GRANULES.NS"
      }
    },
    "llm_analysis": {
      "actionable_summary": {
        "action": "watch",
        "bias": "neutral",
        "headline": "Granules India clears USFDA inspection",
        "rationale": "Regulatory overhang removed but price action weak"
      },
      "between_lines": "Market already priced in USFDA clearance or awaits stronger growth trigger",
      "confidence_score": 65,
      "connections": {
        "affects_directly": [
          "Granules India"
        ],
        "affects_indirectly": [
          "US generic suppliers"
        ],
        "cause_effect_chain": "USFDA clearance \u2192 removes overhang \u2192 maintains export momentum",
        "follow_the_money": "regulatory clearance reduces supply risk"
      },
      "core": {
        "action": "regulatory_resolution",
        "momentum": "neutral",
        "momentum_reasoning": "Stock down 2.3% from previous close despite positive regulatory news; low Hurst (0.19) signals mean-reversion regime",
        "sector": "Healthcare",
        "topic": "USFDA inspection closure",
        "trigger": "USFDA inspection report with single observation resolved"
      },
      "cross_stock_impact": [],
      "data_quality": {
        "article_length_tokens": 45,
        "has_financial_data": false,
        "has_price_data": true,
        "has_sentiment_indicators": true,
        "missing_critical_info": [
          "observation details",
          "financial impact",
          "forward guidance"
        ],
        "overall_quality_score": 0.4
      },
      "deals": {
        "counterparty": [],
        "deal_currency": null,
        "deal_size": null,
        "deal_type": null
      },
      "entities": [
        {
          "name": "Granules India",
          "role": "catalyst",
          "ticker": "GRANULES.NS",
          "type": "company"
        },
        {
          "name": "USFDA",
          "role": "regulator",
          "ticker": null,
          "type": "government"
        }
      ],
      "financials": {
        "buyback": null,
        "data_source": null,
        "dividend": null,
        "funding_amount": null,
        "guidance": null,
        "profit": null,
        "revenue": null,
        "valuation": null
      },
      "market_reaction": {
        "expected_impact": "Neutral; regulatory noise removed",
        "index_impact": [],
        "price_change": "-2.26%",
        "volume_change": null
      },
      "numerical_extractions": {
        "fiscal_period": null,
        "mentioned_prices": [],
        "mentioned_targets": [],
        "poll_source": null,
        "profit_change_pct": null,
        "revenue_change_pct": null,
        "volume_growth_yoy_pct": null
      },
      "patterns": {
        "pattern_reasoning": "No volume surge (volume_multiple 0.75) and price drop contradict accumulation/breakout patterns",
        "pattern_type": null,
        "similar_past_event": null,
        "stage": "completed",
        "strength": "weak"
      },
      "rag_alignment": {
        "rag_company_relevant": "yes",
        "relevance_reasoning": "RAG similarity 0.48 indicates partial relevance; article explicitly names Granules India and its USFDA inspection outcome",
        "should_prioritize_rag": true,
        "similarity_interpretation": "sectoral_relevance"
      },
      "reasoning_chain": [
        "Single observation resolved is positive",
        "But price dropped 2.26% on low volume",
        "Technical metrics show mean-reversion regime",
        "No immediate catalyst for upside"
      ],
      "red_flags": [
        "Price fell despite positive news",
        "Volume 25% below average",
        "Stock below 20-day MA and VWAP"
      ],
      "sentiment": {
        "confidence": 0.7,
        "direction": "positive",
        "drivers": [
          "inspection completed",
          "only one observation",
          "observation already resolved"
        ],
        "intensity": 0.6
      },
      "signals": {
        "crowd_behavior": {
          "source": "inference",
          "value": "apathy"
        },
        "key_levels": {
          "source": "article",
          "values": [
            "554.45",
            "573.75"
          ]
        },
        "price_action_expected": {
          "source": "inference",
          "value": "range"
        },
        "reaction_reasoning": "volume_multiple 0.75 shows no institutional interest; price below VWAP 498.16 and PSAR 574.83 suggests sellers in control",
        "volume_expectation": {
          "source": "inference",
          "value": "normal"
        }
      },
      "smart_money": {
        "big_players": [],
        "evidence": "price decline on below-average volume",
        "retail_position": "neutral",
        "their_likely_motive": "awaiting next catalyst"
      },
      "timing": {
        "catalyst_date": null,
        "expected_duration_days": 7,
        "temporal_anchor": "2025-11-05",
        "urgency": "this_week"
      },
      "trading_angles": [
        {
          "conviction": "low",
          "idea": "Watch for bounce off 554.45 low if volume returns",
          "reasoning": "Mean-reversion signal (Hurst 0.19) but needs volume confirmation",
          "risk": "No follow-through buying"
        }
      ]
    },
    "metrics": {
      "model_params": {
        "max_completion_tokens": 8192,
        "model": "moonshotai/kimi-k2-instruct-0905",
        "reasoning_effort": "medium",
        "stream": false,
        "temperature": 0.4,
        "top_p": 0.9
      },
      "timing": {
        "end_time": "2025-11-05T06:19:37.302141",
        "llm_response_seconds": 2.989,
        "rag_query_seconds": 1.092,
        "start_time": "2025-11-05T06:19:33.220282",
        "total_duration_seconds": 4.082
      },
      "tokens": {
        "actual_from_api": {
          "input_tokens": 4626,
          "output_tokens": 843,
          "total_tokens": 5469
        }
      }
    },
    "rag_match": {
      "company": "Granules India Limited",
      "sector": "Healthcare",
      "similarity_score": 0.480369568,
      "symbol": "GRANULES.NS"
    },
    "timestamp": "2025-11-05T06:19:37.302209"
  },
  "article_id": "c6a9aabd-e07c-4602-8fd7-3feb3fd75422",
  "result_id": "20251105_061937",
  "status": "completed"
}